PDCD1 and neoplasm: Immune checkpoint blockade by specific inhibitors, namely, anti-CTLA-4 and anti-PD-1 inhibitors, is essential in blocking the inhibitory signals of T-cell activation, which allows tumor-reactive T cells to release an effective anti-tumor response [90,139].